Basar Kilic S, Erdal H
Medicine (Baltimore). 2025; 104(10):e41715.
PMID: 40068069
PMC: 11903012.
DOI: 10.1097/MD.0000000000041715.
Liu S, Lv J, Li F, Zhang Y
Sci Rep. 2025; 15(1):6872.
PMID: 40011693
PMC: 11865271.
DOI: 10.1038/s41598-025-91237-z.
Liu Q, Liu J, Zheng Y, Lei J, Huang J, Liu S
Nan Fang Yi Ke Da Xue Xue Bao. 2025; 45(1):90-99.
PMID: 39819717
PMC: 11744291.
DOI: 10.12122/j.issn.1673-4254.2025.01.12.
Armijo-Borjon G, Miranda-Aguirre A, Garza-Silva A, Fernandez-Chau I, Sanz-Sanchez M, Gonzalez-Cantu A
Arch Dermatol Res. 2025; 317(1):195.
PMID: 39775081
DOI: 10.1007/s00403-024-03688-5.
Radu A, Tit D, Endres L, Radu A, Vesa C, Bungau S
Inflammopharmacology. 2024; 33(2):527-549.
PMID: 39576422
PMC: 11842495.
DOI: 10.1007/s10787-024-01602-z.
Xiaoyin-anshen formula alleviates psoriasis complicated by sleep disturbances by regulating melatonin, antioxidant enzymes, and pro-inflammatory cytokines in mice.
Zhu Z, Yin Q, Duan X
Front Pharmacol. 2024; 15:1427985.
PMID: 39411067
PMC: 11473356.
DOI: 10.3389/fphar.2024.1427985.
Mapping the psoriasis research landscape: A comprehensive bibliometric analysis from 2012-2023.
Garg S, Chawla M, Dixit M, Sharma A, Singh M, Singh V
Int J Immunopathol Pharmacol. 2024; 38:3946320241290341.
PMID: 39393083
PMC: 11492216.
DOI: 10.1177/03946320241290341.
A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.
Ghani H, Podwojniak A, J Tan I, Parikh A, Sanabria B, Rao B
Skin Res Technol. 2024; 30(9):e70041.
PMID: 39206797
PMC: 11359094.
DOI: 10.1111/srt.70041.
The impact of lipidome on five inflammatory skin diseases: a Mendelian randomization study.
Zhu X, Wu W
Arch Dermatol Res. 2024; 316(8):565.
PMID: 39177801
DOI: 10.1007/s00403-024-03294-5.
Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
de Moraes-Souza R, Chahine Chater R, Pera Calvi I, Mesquita Y, Sarto R, Lapenda I
Clin Drug Investig. 2024; 44(9):655-665.
PMID: 39172296
PMC: 11455807.
DOI: 10.1007/s40261-024-01368-w.
Improvement of self-administration experience with a new injection device: Real-life experience with risankizumab in patients with psoriasis.
Brunasso A, Salvi I, Sorbara S, Muracchioli A, De Col E, Baldari M
Skin Res Technol. 2024; 30(8):e13902.
PMID: 39162189
PMC: 11333944.
DOI: 10.1111/srt.13902.
Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids.
Gisondi P, Gracia-Cazana T, Kurzen H, Galvan J
J Clin Med. 2024; 13(15).
PMID: 39124750
PMC: 11313259.
DOI: 10.3390/jcm13154484.
Breakthrough Opportunities of Nanotheranostics in Psoriasis: From Pathogenesis to Management Strategy.
Singh A, Kumar P, Sharma H
Infect Disord Drug Targets. 2024; 25(2):e230724232190.
PMID: 39075964
DOI: 10.2174/0118715265298802240603120251.
Therapeutic Effect of Lecigel, CetiolCC, Activonol-6, Activonol-M, 1,3-Propanediol, Soline, and Fucocert (LCAA-PSF) Treatment on Imiquimod-Induced Psoriasis-like Skin in Mice.
Li C, Lin C, Lee C, Sheu M, Tsai Y, Tsai C
Int J Mol Sci. 2024; 25(14).
PMID: 39062965
PMC: 11276952.
DOI: 10.3390/ijms25147720.
New Insights in Psoriasis Management using Herbal Drug Nanocarriers.
Salgaonkar S, Purewal J, Doshi G, Fernandes T, Gharat S, Sawarkar S
Curr Pharm Des. 2024; 30(32):2550-2561.
PMID: 39051579
DOI: 10.2174/0113816128330298240708110336.
Biochanin A Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice by Modulating the NF-κB and MAPK Signaling Pathways.
Walvekar K, Tirunavalli S, Eedara A, Chandra Y, Kuncha M, B R Kumar A
Inflammation. 2024; .
PMID: 39017810
DOI: 10.1007/s10753-024-02103-5.
Ruptured abdominal aortic aneurysm in psoriasis: A case report and review of literature.
Mouhanni S, Hassani A, Lekehal M, Bounssir A, Bakkali T, Lekehal B
Int J Surg Case Rep. 2024; 120:109829.
PMID: 38870660
PMC: 11225200.
DOI: 10.1016/j.ijscr.2024.109829.
Clinical implications for the association of psoriasis and multiple sclerosis: an observational study.
Miele G, Sparaco M, Maida E, Bile F, Lavorgna L, Bonavita S
Neurol Sci. 2024; 45(11):5395-5403.
PMID: 38822164
PMC: 11470866.
DOI: 10.1007/s10072-024-07616-3.
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.
Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S
Clin Cosmet Investig Dermatol. 2024; 17:1037-1042.
PMID: 38737943
PMC: 11088372.
DOI: 10.2147/CCID.S464326.
RNA-Based Antipsoriatic Gene Therapy: An Updated Review Focusing on Evidence from Animal Models.
Lin Z, Hung C, Aljuffali I, Lin M, Fang J
Drug Des Devel Ther. 2024; 18:1277-1296.
PMID: 38681207
PMC: 11055533.
DOI: 10.2147/DDDT.S447780.